Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor (SNRI) that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents. Strattera is a prescription medication that is used to treat ADHD, and is the brand name for atomoxetine. Strattera is a selective norepinephrine reuptake inhibitor (SNRI) that is used to treat ADHD in adults. Strattera is a medication that belongs to the group of drugs called norepinephrine reuptake inhibitors (NRI). NRI works by blocking the reabsorption of certain neurotransmitters in the brain that influence attention, behavior, and impulse control. Strattera is available in a 5 mg, 10 mg, and 20 mg dosage strengths.

Atomoxetine is used to treat ADHD. It is also the brand name for Strattera. It works by increasing the levels of norepinephrine in the brain and helping to improve attention and impulse control. NRI works by blocking the reabsorption of certain neurotransmitters in the brain and helping to improve attention, behavior, and impulse control.

Atomoxetine is available in the following strengths:

Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents. Atomoxetine is a medication that is used to treat ADHD in adults. Atomoxetine is available in a 5 mg, 10 mg, and 20 mg dosage strengths. Atomoxetine is available in the following strengths: Atomoxetine is a medication that is used to treat ADHD.

Atomoxetine is available in the following strengths: Strattera is a medication that is used to treat attention deficit hyperactivity disorder (ADHD) in adults. Strattera is a medication that is used to treat ADHD in adults. Atomoxetine is available in the following strengths: Strattera is a medication that is used to treat ADHD. Atomoxetine is available in the following strengths: Atomoxetine is a medication that is used to treat attention deficit hyperactivity disorder (ADHD) in adults. Strattera is a medication that is used to treat ADHD. Strattera is available in the following strengths: Atomoxetine is a medication that is used to treat attention deficit hyperactivity disorder (ADHD) in adults.

Show more

Atomoxetine is a medication that belongs to the group of drugs called norepinephrine reuptake inhibitors (NRI).

Product description

Product name:STRATTERA

Company name:

DIN:0224866

Status:Marketed

Status date:2018-02-10

Active ingredient(s)	Strength
NO. SIXTH MIXTH SULFATE	100 MG

Resources

Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.

For consumers

Resource	Description
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections: Part I: Health Professional Information; Part II: Scientific Information; and Patient Medication Information
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are: Unexpected, regardless of their severity, i.e., not consistent with product information or labelling; or Serious, whether expected or not, i.e., that requires being admitted to the hospital, lengthened hospital stay, causes a birth defect, disability, is life-threatening or results in death; Reactions to recently marketed health products (on the market for less than five years), regardless of their nature or severity.

For health care professionals

Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals.

For researchers

After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes.

All resources

Atomoxetine (Strattera) is a non-stimulant medication used to treat attention deficit hyperactivity disorder (ADHD). It is also prescribed for the treatment of narcolepsy, which is characterized by excessive sleep. Strattera is known to cause insomnia.

What Are the Side Effects of Atomoxetine?

The common side effects of Atomoxetine include:

• Constipation
• Stomach pain
• Dry mouth
• Dizziness
• Fatigue
• Drowsiness
• Blurred vision
• Headache
• Weight gain
• Abnormal vision
• Increased blood pressure
• Increased heart rate
• Diarrhea

If you are using Strattera or any other medication, you should not take Atomoxetine without consulting a doctor first.

How Long Does Atomoxetine Take to Work?

The average onset of action for Atomoxetine is 20 minutes, but you may take it up to 4 hours before bed. The onset of action may vary depending on your specific situation. Your doctor will tell you how long you should stay in bed.

If you take atomoxetine for the entire duration of your treatment, you should expect to have a significant improvement in your symptoms within 30 minutes of the first dose. Atomoxetine should not be taken by someone who is hypersensitive to it, as it can cause an upset stomach. However, some people with a history of gastrointestinal bleeding or perforation of the gastrointestinal tract also have this issue.

If you are using atomoxetine for the entire duration of your treatment, your doctor will tell you how long you should stay in bed. This is because you may need to stay in bed for up to 6 hours after taking atomoxetine. If you are taking any other medications that can affect the effectiveness of atomoxetine, your doctor will likely not prescribe it.

If you are using atomoxetine for the entire duration of your treatment, you should expect to have a significant improvement within 30 minutes of the first dose.

It is not clear whether atomoxetine is safe for most people. Atomoxetine is not a controlled substance, so it will not affect your ability to have a normal sleep. It may be safe for some people to use it if they are already taking other medications, but it is not recommended for children and adolescents.

What Happens if I Take Atomoxetine?

Taking atomoxetine for the entire time of your treatment is not recommended because it can cause an upset stomach. If you take any medication that can affect the effectiveness of atomoxetine, your doctor will likely not prescribe it. Atomoxetine may not be safe for people who are using other medications. It is also not safe for people who are taking other medications that can affect the effectiveness of atomoxetine, such as acetaminophen.

When using atomoxetine for the entire duration of your treatment, you should expect to have a significant improvement in your symptoms within 30 minutes of the first dose. Atomoxetine may be safe for some people to use if they are already taking other medications, but it is not recommended for children and adolescents.

If you are using atomoxetine for the entire time of your treatment, you should expect to have a significant improvement within 30 minutes of the first dose.

Strattera (Atomoxetine)

Brand Name(Strattera)

Strattera (atomoxetine) is a prescription medication that belongs to a class of drugs known as selective norepinephrine reuptake inhibitors. It is primarily used to treat Attention-Deficit/Hyperactivity Disorder (ADHD).

Strattera is the brand name for atomoxetine. It is a selective norepinephrine reuptake inhibitor (NRI). Strattera is a prescription medication that belongs to a class of drugs known as N-methyl-d-aspartate (NMDA) receptor antagonists.

Strattera is a commonly prescribed medication for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The main indications for Strattera are:

•Attention-deficit/hyperactivity disorder (ADHD)•Attention-untightness/control (attention-related memory)•Attention-impulsivity (impaired memory)•Attention-impulsivity/hypnotia (anxiety)

Strattera is not the first drug to be approved for this condition.

What is Strattera?

It is used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and other ADHD symptoms.

Strattera is a prescription medication that is used to treat Attention-Deficit/Hyperactivity Disorder (ADHD). It is used to treat attention deficit/hyperactivity disorder,, and other ADHD symptoms.

•Attention-deficit/hyperactivity disorder•Attention-impulsivity (impaired attention span)•Hyperactivity•Attention-restless•Hyperactivity•Attention-impulsivity/hypnotia•Attention-restless•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity•Hyperactivity

How does Strattera work?

Strattera belongs to a group of drugs known as selective norepinephrine reuptake inhibitors (SNRIs).

INDIANAPOLIS, Oct. 20, 2004 /PRNewswire/ -- Mylan Pharmaceuticals Inc. today announced that the U. S. Food and Drug Administration approved the first generic version of Strattera, a medicine for treating Attention Deficit Hyperactivity Disorder (ADHD) in adults and adolescents 18 years of age and older.

"This approval represents an important step forward in our efforts to advance our therapeutic portfolio of innovative products for ADHD," said David M. Rosen, M. D., Chief Executive Officer of Mylan Pharmaceuticals.

ADHD is the most common type of Attention Deficit Hyperactivity Disorder (ADHD). It is estimated that approximately one million American adults have ADHD, making it the most common type of ADHD. The prevalence of ADHD in adults in the United States is estimated at about 1.5% of the population, and is projected to increase with age.

Currently, Strattera is under development. Strattera is being evaluated in clinical trials for a new formulation of the drug, Strattera-R.

Currently, Strattera-R is currently being marketed for treatment of ADHD in adults. Strattera-R was approved by the FDA in November 2000 for the treatment of ADHD in adults and adolescents, and is currently being marketed by Mylan Pharmaceuticals Inc. and GlaxoSmithKline.

Strattera is available in generic form, priced at $4.90 per pill.

For more information about Strattera and the development and manufacturing of generic Strattera please visit the Strattera Web site at or visit the Mylan Pharmaceuticals website at www.mylanpharmacy.com.

The U. Food and Drug Administration approved Strattera in November 2000 for the treatment of ADHD in adults and adolescents, and is currently the second most prescribed medicine in the United States.

For more information about the development and manufacturing of generic Strattera please visit the Mylan Pharmaceuticals website at www.mylanpharmacy.com

About Mylan Pharmaceuticals Inc.

Mylan Pharmaceuticals Inc. is an innovative biopharmaceutical company developing, marketing and delivering innovative medicines to consumers worldwide. The company is based in Indianapolis, Indiana.

SOURCE Mylan Pharmaceuticals Inc.

Media Enquiries:Investor ID: Dan M. Rosen

Phone: 616-808-1765

Investor Number: 813-845-5109

Investor Number: Michael D. Metzger

Phone: 615-646-2900

Investor Name: Elizabeth G. Gebreten

Phone: 813-846-4ricia

Investor Name: Mary L. Mabry

Phone: 513-646-9669

Investor Name: Michael D.

Phone: 615-646-2903

Investor Name: Laura L. Smith

Phone: 513-646-9800

Investor Name: Michael L.

Phone: 615-646-5104

Investor Name: Richard W. Hutter

Phone: 616-746-2900

Investor Name: Carol J. Pascual

Phone: 615-646-3201

Investor Name: Lisa J. Leucht

Phone: 513-646-8708

Investor Name: Carol W. Wollman

Phone: 513-646-1740

Investor Name: Lacy M. Williams

Phone: 513-646-4100

Phone: 513-646-5106

Investor Name: Michael J. JohnsonInvestor Name: David G. WickerPate

Phone: 513-646-3201

Investor Name: David M. Rittenhouse

Phone: 513-646-6208

Investor Name: John M. HorseritInvestor Name: John J.

Atomoxetine (Strattera) is part of a class of medications called selective norepinephrine reuptake inhibitors (SNRIs). SNRIs like atomoxetine work by preventing the reuptake of nerve signals in the brain.

Atomoxetine is in a class of medications called norepinephrine-dopamine reuptake inhibitors (NDRIs). NDRIs work by increasing the levels of norepinephrine in the brain. NNRIs are commonly prescribed for treating ADHD, OCD, panic disorder, and other psychiatric disorders.

Advertisement

Cleveland Clinic Pharmacy is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic pharmacy products or services. This site does not store any pharmacist/pharmacy material. We also ask that you be directed to the pharmacy’s product specifications for each and every pharmacy you may be chance to buy. This ensures you receive the best price. Adgeon generalOur website helps our visitors to access this site. We ask that you be careful what you want from us. We also ask that you be careful what you buy. We ask that you be careful what you buy.